Possible role of mevalonate in the hypercholesterolemia seen in experimental chronic renal failure

M. C. Subang, J. L. Stewart-Phillips, A. S. Pappu, R. Subang, R. F. Gagnon

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Hypercholesterolemia may contribute to the pathogenesis of atherosclerosis associated with chronic renal failure (CRF). The mechanism underlying CRF-induced hypercholesterolemia, however, is still unknown. Mevalonate is the direct product of the rate-limiting step in cholesterol synthesis which is catalyzed by 3-hydroxy-3-methylglutaryl coenzyme A reductase. We studied the changes in mevalonate metabolism in a mouse model of CRF in which serum total cholesterol levels are directly correlated with the degree of severity of the disease as measured by serum urea levels. The results of these experiments indicated that in CRF mice, the urine mevalonate levels were significantly lower, while serum mevalonate and total cholesterol levels were significantly higher than in normal mice. We believe that by restricting the normal urinary excretion of mevalonate CRF results in more of this precursor being available for direct cholesterol synthesis. In addition, an increase in circulating mevalonate may upregulate the shunt pathway of mevalonate metabolism in the liver and peripheral tissues, thus providing increased levels of the substrates acetoacetate and acetyl coenzyme A for cholesterol synthesis.

Original languageEnglish (US)
Pages (from-to)151-154
Number of pages4
Issue number2
StatePublished - 1995
Externally publishedYes


  • Cholesterol
  • Chronic renal failure, mouse model
  • Mevalonate

ASJC Scopus subject areas

  • Physiology
  • Nephrology
  • Physiology (medical)
  • Urology


Dive into the research topics of 'Possible role of mevalonate in the hypercholesterolemia seen in experimental chronic renal failure'. Together they form a unique fingerprint.

Cite this